These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 14571410)
1. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Hricak H; Schöder H; Pucar D; Lis E; Eberhardt SC; Onyebuchi CN; Scher HI Semin Oncol; 2003 Oct; 30(5):616-34. PubMed ID: 14571410 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure? Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322 [TBL] [Abstract][Full Text] [Related]
4. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy. Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540 [TBL] [Abstract][Full Text] [Related]
5. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide? Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339 [TBL] [Abstract][Full Text] [Related]
6. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294 [TBL] [Abstract][Full Text] [Related]
7. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572 [TBL] [Abstract][Full Text] [Related]
8. Imaging of prostate cancer. Akin O; Hricak H Radiol Clin North Am; 2007 Jan; 45(1):207-22. PubMed ID: 17157630 [TBL] [Abstract][Full Text] [Related]
10. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265 [TBL] [Abstract][Full Text] [Related]
11. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. Winter A; Henke RP; Wawroschek F BMC Urol; 2015 Feb; 15(1):10. PubMed ID: 25881245 [TBL] [Abstract][Full Text] [Related]
12. Prostate cancer imaging. Kundra V Semin Roentgenol; 2006 Apr; 41(2):139-49. PubMed ID: 16697892 [No Abstract] [Full Text] [Related]
13. Positron emission tomography for prostate, bladder, and renal cancer. Schöder H; Larson SM Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005 [TBL] [Abstract][Full Text] [Related]
14. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082 [TBL] [Abstract][Full Text] [Related]
16. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Haseman MK; Reed NL; Rosenthal SA Clin Nucl Med; 1996 Sep; 21(9):704-13. PubMed ID: 8879871 [TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476 [TBL] [Abstract][Full Text] [Related]
20. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. Linder BJ; Kawashima A; Woodrum DA; Tollefson MK; Karnes J; Davis BJ; Rangel LJ; King BF; Mynderse LA Can J Urol; 2014 Jun; 21(3):7283-9. PubMed ID: 24978358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]